Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | OXTR | P30559 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600173 | 0.93 | HCRTR1 (0.51) | HCRTR1HCRTR2MEN1KMT2AOXTR | |
| SCHEMBL4470460 | 0.88 | HCRTR2 (0.62) | HCRTR1HCRTR2OXTRAVPR1A | |
| SCHEMBL4459163 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2OXTRLMNA | |
| SCHEMBL4457211 | 0.86 | HCRTR1 (0.50) | HCRTR1HCRTR2OXTRLMNAAVPR1A | |
| SCHEMBL4459456 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2OXTRLMNAAVPR1A | |
| SCHEMBL4461806 | 0.83 | HCRTR2 (0.61) | HCRTR1HCRTR2OXTRAVPR1A | |
| SCHEMBL4464707 | 0.83 | KMT2A (0.52) | HCRTR1HCRTR2MEN1KMT2AOXTR | |
| SCHEMBL4457691 | 0.83 | OXTR (0.56) | HCRTR1HCRTR2MEN1KMT2AOXTR | |
| SCHEMBL4453885 | 0.82 | HCRTR2 (0.46) | HCRTR1HCRTR2OXTRLMNAAVPR1A | |
| SCHEMBL4455651 | 0.82 | HCRTR2 (0.57) | HCRTR1HCRTR2OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007019234-A2 | AMINOETHANE SULFONAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPSR1 | HCRTR1 2/4885HCRTR2 1/4885MEN1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.